Takeaways
#- Semiconductors had cleared resistance against small caps; the broader technology fund had not.
- Zarling compared XBI with both IBB and IWM before choosing smaller biotechs over a broad small-cap allocation.
- Thwaites was looking for individual companies in XBI, while Parets cautioned against judging their prospects by the Dow or Nasdaq 100.
David Zarling had a biotech position when he joined Spencer Israel and JC Parets on February 28, 2024. He traced the decision back to the broad advance in November and December. When a large number of stocks began rising together, which ones did investors buy first? Among small caps, he said, they bought biotechs. That gave him a place to look when the rally resumed, even before he had a strong preference for small caps over large ones.
The technology comparison was still undecided
Zarling showed the Technology Select Sector SPDR Fund (XLK) relative to the iShares Russell 2000 ETF (IWM). The ratio was testing an area that went back to the dot-com era. Someone deciding where to put the next dollar could make a case for either side. A move through that area would strengthen the argument for technology. Semiconductors had already cleared their comparable level against small caps, but the rest of technology had yet to follow.
The two technology charts measured different portfolios. Parets noted how much influence Apple and Microsoft had in XLK. A strong semiconductor group could carry its own index higher even while those two stocks held the broader fund back.
Zarling saw room for small caps to recover: the S&P 500 had reached new highs while the small-cap index was still more than 20% below its peak. But being further from a high wasn’t enough to win an allocation. He wanted small caps to hold the December level on his relative chart. If they lost it, sitting in the laggard would mean passing up gains elsewhere.
Why he singled out XBI
Parets asked whether small-cap leadership required both biotech and regional banks to work. Zarling said no. He compared the SPDR S&P Biotech ETF (XBI) with the iShares Biotechnology ETF (IBB). XBI gave smaller companies more influence; the larger businesses carried more weight in IBB. On his charts investors were favoring the smaller names. XBI was also outperforming IWM, giving him a reason to choose the industry over the broad index. He saw little reason to add regional banks simply because they also belonged to the small-cap universe.
Parets pulled up two lists of biotechs worth between $1 billion and $30 billion. One was sorted for new 52-week highs, the other for all-time highs. Very few of those companies fell in the $10 billion to $30 billion range, he said. Looking at the individual names exposed just how much of the strength was coming from further down the size scale.
Mary Thwaites had been watching both XBI and IWM for signs that traders were willing to take more risk. She was working through XBI’s holdings for individual ideas. Parets offered a narrower reading: a good market for small biotech stocks could coexist with a sluggish Dow or Nasdaq 100.
Questions and answers
#Questions answered in the original 2024-02-28 episode.
Why did Zarling compare XBI with IBB?
The two funds emphasized different company sizes. The relative chart favored XBI, where smaller biotech stocks had more influence.
What would weaken the case for small caps?
Zarling wanted the small-cap relative chart to hold its December level. If it lost that level, he would favor the larger stocks again.
Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .